Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.55 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18118011 | 1.00 | EGFR (0.76) | EGFRKMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL7199485 | 0.99 | EGFR (0.78) | EGFRKMT2AHDAC3HDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL21542083 | 0.87 | PTGS2 (0.59) | EGFRKMT2AHDAC3HDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL31430469 | 0.87 | PTGS2 (0.59) | EGFRKMT2AHDAC3HDAC1HDAC2 | |
| N-Dodecylcinnamamide SCHEMBL16596238 | 0.87 | EGFR (1.00) | EGFRKMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL28975079 | 0.87 | EGFR (1.00) | EGFRKMT2AHDAC3HDAC1HDAC2 | |
| N-Hexadecylcinnamamide SCHEMBL2727701 | 0.87 | EGFR (1.00) | EGFRKMT2AHDAC3HDAC1HDAC2 | |
| N-Octylcinnamamide SCHEMBL10706126 | 0.87 | EGFR (1.00) | EGFRKMT2AHDAC3HDAC1HDAC2 | |
| N-Dodecylcinnamamide SCHEMBL28975087 | 0.87 | EGFR (1.00) | EGFRKMT2AHDAC3HDAC1HDAC2 | |
| N-Pentylcinnamamide SCHEMBL7913716 | 0.86 | EGFR (0.97) | EGFRKMT2AHDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205436-B2 | Process for manufacture of quaternary ammonium tosylate salts of cinnamidoalkylamines and / or benzamidoalkylamines | GALAXY SURFACTANTS LIMITED (IN) | 2007-04-17 | — | — | US | disclosed |
| US-7045139-B2 | Process for manufacture of quaternary ammonium tosylate salts of cinnamidoalkylamines and/or benzamidoalkylamines | GALAXY SURFACTANTS LIMITED (IN) | 2006-05-16 | — | — | US | disclosed |
| US-20050209327-A1 | Novel process for manufacture of quaternary ammonium tosylate salts of cinnamidoalkylamines and / or benzamidoalkylamines | GALAXY SURFACTANTS LTD. (IN) | 2005-09-22 | — | — | US | disclosed |
| US-20050080135-A1 | Novel process for manufacture of quaternary ammonium tosylate salts of cinnamidoalkylamines and/or benzamidoalkylamines | GALAXY SURFACTANTS LTD. (IN) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209327-A1 | Novel process for manufacture of quaternary ammonium tosylate salts of cinnamidoalkylamines and / or benzamidoalkylamines | NISCH, CUTA, PFAS | EGFR 1822/4885KMT2A 899/4885HDAC3 2205/4885 |
| US-20050080135-A1 | Novel process for manufacture of quaternary ammonium tosylate salts of cinnamidoalkylamines and/or benzamidoalkylamines | NISCH, CUTA, PFAS | EGFR 1822/4885KMT2A 899/4885HDAC3 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.